skip navigation

PUBLICATIONS

Register for Latest Research

Stay Informed
Register with NCJRS to receive NCJRS's biweekly e-newsletter JUSTINFO and additional periodic emails from NCJRS and the NCJRS federal sponsors that highlight the latest research published or sponsored by the Office of Justice Programs.

NCJRS Abstract

The document referenced below is part of the NCJRS Virtual Library collection. To conduct further searches of the collection, visit the Virtual Library. See the Obtain Documents page for direction on how to access resources online, via mail, through interlibrary loans, or in a local library.

 

NCJ Number: 201922 Find in a Library
Title: Differential Pharmacological Treatment of Paraphilias and Sex Offenders
Journal: International Journal of Offender Therapy and Comparative Crminology  Volume:47  Issue:4  Dated:August 2003  Pages:407-421
Author(s): Andreas Hill; Peer Briken; Christian Kraus; Kerstin Strohm; Wolfgang Berner
Date Published: August 2003
Page Count: 15
Publisher: http://www.sagepub.com 
Type: Issue Overview
Format: Article
Language: English
Country: United States of America
Annotation: This article discusses pharmacological treatment of paraphilias and sex offenders in Germany.
Abstract: The interest in pharmacological treatments of paraphilias and sex offenders has been increasing in the past decade. The optimal pharmacotherapy for paraphilias should reduce the sexual deviant behavior and not cause other adverse side effects. Selective Serotonin Reuptake Inhibitors (SSRIs) may cause general inhibition of sexual activity, and the reduction of impulsiveness, obsessive-compulsive characteristics, underlying depressive symptoms, and an indirect reduction of testosterone serum levels. Androgens (testosterone and dihydrotestosterone) play a crucial role in the hormonal regulation of male sexuality. Antihormonal substances, such as cyproterone acetate/CPA, medroxyprogesterone acetate/MPA, and luteinizing hormone-releasing hormone agonists (LHRH agonists), were tested on patients with deviant sexual behavior. Both the results of open, uncontrolled clinical studies with SSRIs and LHRH agonists in paraphilic outpatients confirm the positive effects of these substances. A survey was conducted in German hospitals on the use of CPA and LHRH agonists. The results show that half of the patients treated with any kind of (anti-) hormonal agents received a LHRH agonist. The side effects of these agents involved changes in blood pressure, weight gain, temporary renal dysfunction, and osteoporosis. A treatment program should start with supportive or intensive cognitive behavioral or psychodynamic psychotherapy and pharmacological treatment of comorbid disorders if needed. In mild cases with strong deviant fantasies or impulses and any risk for sexual offenses, psychotherapy in combination with SSRI treatment should be considered, especially if the paraphilia is less severe, and if the paraphilic patient shows additional symptoms, such as anxiety, depression, and obsessions. CPA or MPA should be given if there is an insufficient improvement and a moderate to high risk for hands-on offenses. LHRH agonists seem to be effective in some cases in which CPA and SSRIs failed. 2 figures, 63 references
Main Term(s): Drug therapy; Sex offender treatment
Index Term(s): Germany; Mandatory sex offender treatment; Medical model of offender treatment; Treatment; Treatment effectiveness; Treatment offender matching
To cite this abstract, use the following link:
http://www.ncjrs.gov/App/publications/abstract.aspx?ID=201922

*A link to the full-text document is provided whenever possible. For documents not available online, a link to the publisher's website is provided. Tell us how you use the NCJRS Library and Abstracts Database - send us your feedback.